Medication info
Linatin Plus Tablet 2.5/850 mg

Linatin Plus Tablet 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Bright orange, oval-shaped, biconvex film-coated tablet
Packaging
PTP - 10 tablets/PTP [x6 packs]
Approval status
Active

MFDS item code 202300413 · Approved 2023.01.31 · Insurance code 645406430

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently treated with metformin: For patients with no previous experience of antidiabetic drug therapy and inadequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily, which may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients with inadequate glycemic control on combination therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is used in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication is recommended to be used in conjunction with diet and exercise to assist patients with type 2 diabetes in controlling their blood sugar levels. Linagliptin and metformin work together to effectively manage blood glucose levels. Therefore, it is used for the treatment of type 2 diabetes requiring blood sugar management.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently treated with metformin: For patients with no previous experience of antidiabetic drug therapy and inadequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily, which may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients with inadequate glycemic control on combination therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is used in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication aids in blood sugar control. However, it can cause a rare side effect called lactic acidosis, which must be approached with utmost caution. Lactic acidosis occurs when there is an excessive accumulation of lactic acid in the body, which can lead to serious conditions; therefore, it is safer for individuals with poor kidney function or those with heart disease or liver dysfunction not to take this medication. Additionally, those with known allergies to any components of this medication, type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or acute conditions such as infections or trauma should not use this medication. Pregnant or breastfeeding women are also advised against using this medication. This medication poses a risk of hypoglycemia; therefore, when taken with other hypoglycemic agents such as insulin or sulfonylureas, blood glucose levels should be monitored closely. It is also important to regularly test kidney function for abnormalities, and elderly patients should be especially cautious as decreased kidney function is common in this group. If sudden abdominal pain, persistent muscle weakness, or difficulty breathing occurs while taking this medication, consult a doctor immediately. Rare skin diseases such as acute pancreatitis or blistering similar to pemphigus should also be reported immediately if symptoms arise. Moreover, this medication may reduce vitamin B12 levels; hence, it is advisable to regularly check vitamin B12 levels if used for prolonged periods. Alcohol consumption may increase the risk of lactic acidosis, thus it's best avoided. This medication can interact with other drugs, so patients must inform their doctors or pharmacists of any other medications they are taking. Caution is particularly necessary when taken with drugs that may affect kidney function or glycemia. Lastly, this medication is not recommended for use in children or in those under 10 years old, and research on its effects on driving or operating machinery is insufficient, so caution is warranted. Keep the medication out of reach of children and avoid humid places during storage.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • dysgeusia
  • cough
  • appetite loss
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 104 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • oral ulcer
  • constipation
  • stomatitis
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • dysarthria
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • renal transplant failure
  • pneumonia
  • hypertension
  • pruritus
  • insomnia
  • depression
  • anxiety
  • angina
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • gingivitis
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • dizziness
  • drowsiness
  • chest discomfort
  • weakness
  • pain
  • nosebleed
  • oropharyngeal pain
  • voice disorders
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • goiter
  • confusion
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture; therefore, it must be stored in a tightly sealed container. Additionally, it is important to maintain its efficacy by storing it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright orange, oval-shaped, biconvex film-coated tablet

Package unit

PTP - 10 tablets/PTP [x6 packs]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.